Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs


Autoři: Irene B. Murimi-Worstell aff001;  Jeromie M. Ballreich aff002;  Marissa J. Seamans aff002;  G. Caleb Alexander aff001
Působiště autorů: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America aff001;  Center for Drug Safety and Effectiveness, Johns Hopkins University, Baltimore, Maryland, United States of America aff002;  Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America aff003;  Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America aff004;  Division of General Internal Medicine, Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland, United States of America aff005
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225109

Souhrn

Despite the importance of pharmacopeial standards, little is known regarding their effect on drug competition. Such information is of particular relevance given the rising costs of prescription drugs and the focus of policy-makers and other stakeholders on addressing these costs. We examined 982 prescription drugs approved by U.S Food and Drug Administration since 1982 to examine the association between U.S. Pharmacopeia (USP) standards, generic entry and prescription costs. The presence of a USP drug product monograph was not associated with the time to the third generic entrant or with the likelihood of having a generic competitor. However, on average, drugs with USP drug product monographs had approximately fifty percent more generic manufacturers in the U.S. than their counterparts after accounting for factors such as market volume, age, route of administration and vintage. This greater competition was associated with an approximate savings of $6.22 billion in 2016, suggesting that USP drug product monographs may play an important role in promoting pharmaceutical competition and reducing prescription drug costs.

Klíčová slova:

Drug administration – Drug discovery – Drug information – Drug research and development – Drug screening – Drug users – Routes of administration – Drug marketing


Zdroje

1. IQVIA Institute for Healthcare Informatics Medicine use and spending in the US: a review of 2017 and outlook to 2022.; April 2018. Available at https://www.iqvia.com/institute/reports/medicine-use-and-spending-in-the-us-review-of-2017-outlook-to-2022, Accessed on 9.19.2018

2. DiJulio B, Firth J, Brodie M. Kaiser health tracking poll: August 2015. Menlo Park, CA: The Henry J. Kaiser Family Foundation. 2015 Sep.

3. Association for Accessible Medicines. The Case for Competition: 2019 Generic Drug and Biosimilars Access and Savings in the U.S Report. Available at https://accessiblemeds.org/sites/default/files/2019-09/AAM-2019-Generic-Biosimilars-Access-and-Savings-US-Report-WEB.pdf. Accessed on 10.25.2019

4. Association of Accessible Medicines. Generic Drug Access and Savings in the U.S. (2017) Available at: https://accessiblemeds.org/sites/default/files/2017-07/2017-AAM-Access-Savings-Report-2017-web2.pdf. Accessed on 9.19.2018

5. Food US. Drug Administration Safety and Innovation Act. Public law. 2012 Jul:112–44.

6. Center for Drug Evaluation and Research, US Food and Drug Administration. Good ANDA Submission Practices: Guidance for Industry (2018) Available at https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM591134.pdf Accessed on 9.27.2019

7. Anderson L, Higby G. The spirit of voluntarism: a legacy of commitment and contribution: the United States pharmacopeia 1820–1995. United States Pharmacopeial; 1995 Sep 1.

8. Heller WM. The United States Pharmacopeia Its Value to the Professions. JAMA. 1970 Jul 27;213(4):576–9. 4914287

9. USP-NF, General Notices: 4. Monographs and General Chapters. Available at: https://online.uspnf.com/uspnf Accessed on 10.15.2018

10. Bhattacharyya L, Cecil T, Dabbah R, Roll D, Schuber S, Sheinin EB, et al. The value of USP public standards for therapeutic products. Pharmaceutical research. 2004 Oct 1;21(10):1725–31. doi: 10.1023/b:pham.0000045222.01170.4c 15553215

11. Heller WM. Rethinking some USP-FDA relationships. Journal of parenteral science and technology: a publication of the Parenteral Drug Association. 1986;40(3):80–1.

12. U.S. Pharmacopeial Convention. USP and FDA–Working Together to Protect Public Health. USP website. Available at: http://www.usp.org/about/public-policy/usp-fda-roles Accessed 9.19.2018

13. Heyward J, Padula W, Tierce JC, Alexander GC. The Value of US Pharmacopeial Standards: A Review of the Literature. Journal of pharmaceutical sciences. 2018 Jun 13.

14. U.S Food and Drug Administration, Center for Drug Evaluation and Research (U.S.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. [Rockville, Md.]: 2018. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm>. Accessed on April 3, 2018.

15. United States Pharmacopeia and National Formulary (USP 41-NF 36). Rockville, MD: United States Pharmacopeial Convention; 2018. https://www.uspnf.com/ Accessed April 3, 2018.

16. IQVIA, IQVIA World Review. Copyright 2018, reprinted with permission. All rights reserved https://www.iqvia.com/ Accessed April 3, 2018.

17. U.S Food and Drug Administration. National Drug Code Directory, 2018. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory. Accessed on April 3, 2018.

18. Dave CV, Hartzema A, Kesselheim AS. Prices of generic drugs associated with numbers of manufacturers. New England Journal of Medicine. 2017 Dec 28;377(26):2597–8. doi: 10.1056/NEJMc1711899 29281576

19. Derbyshire M. Promoting a competitive generics market in the US. Generics and Biosimilars Initiative Journal. 2016 Mar 1;5(1):45–6.

20. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. Jama. 2016 Aug 23;316(8):858–71. doi: 10.1001/jama.2016.11237 27552619

21. Jones GH, Carrier MA, Silver RT, Kantarjian H. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood. 2016 Jan 1.

22. Federal Trade Commission. Pay-for-delay: how drug company pay-offs cost consumers billions. An FTC Staff Study. 2010 Jan. Available at https://www.ftc.gov/reports/pay-delay-how-drug-company-pay-offs-cost-consumers-billions-federal-trade-commission-staff Accessed on 9.19.2018

23. Sarpatwari A, Avorn J, Kesselheim AS. Using a drug-safety tool to prevent competition. New England Journal of Medicine. 2014 Apr 17;370(16):1476–8. doi: 10.1056/NEJMp1400488 24738666

24. Butler HN. REMS-Restricted Drug Distribution Programs and the Antitrust Economics of Refusals to Deal with Potential Generic Competitors. Fla. L. Rev. 2015;67:977.

25. Morton FS, Boller L. Enabling competition in pharmaceutical markets. Brookings, Brookings. 2017 May 1;2. Available at https://www.brookings.edu/wp-content/uploads/2017/05/wp30_scottmorton_competitioninpharma1.pdf Accessed on 9.19.2018

26. Lietzan Erika, A Second Look at the CREATES Act: What's Not Being Said (September 28, 2016). The Federalist Society Review, Volume 17, Issue 3, Forthcoming; University of Missouri School of Law Legal Studies Research Paper No. 2016–26. Available at SSRN: https://ssrn.com/abstract=2845041


Článek vyšel v časopise

PLOS One


2019 Číslo 11